Drugs Made in America Acquisition Ii CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Drugs Made in America Acquisition II Corp. reports Q1 2026 results, with net income driven by trust account interest, while continuing search for a business combination.
NASDAQ
Drugs Made in America Acquisition II Corp. reports Q3 2025 results, having completed its $500 million IPO and commenced its search for a pharmaceutical business combination target.